{"filing":{"accession_number":"0001193125-26-248242","cik":"0001070494","ticker":"ACAD","company_name":"ACADIA PHARMACEUTICALS INC","form":"8-K","filing_date":"2026-05-29","report_date":null,"primary_document":"d140910d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1070494/000119312526248242/d140910d8k.htm"},"events":[{"id":8113,"run_id":7121,"accession_number":"0001193125-26-248242","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"ACADIA held its Annual Meeting on May 29, 2026, with shareholders voting on and approving multiple matters including the election of three Class I directors (James M. Daly, Edmund P. Harrigan, and Adora Ndu), advisory approval of named executive officer compensation, ratification of Ernst \u0026 Young LLP as auditor, and approval of an amendment to the 2024 Equity Incentive Plan increasing authorized shares by 5,209,670.","company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","filing_date":"2026-05-29","form":"8-K","submitted_at":null,"items":[{"id":2706,"accession_number":"0001193125-26-248242","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of an amendment to the Company's 2024 Equity Incentive Plan that increases the aggregate number of shares authorized for issuance by 5,209,670 shares. This is a material compensatory arrangement affecting the equity incentive plan available to officers and directors. The filing explicitly references Item 5.02(e), which governs compensatory arrangements, and the amendment directly impacts the pool of equity available for future grants to named executives and directors.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-30T02:13:01.237710+00:00","company_name":"","ticker":null,"filing_date":""},{"id":2707,"accession_number":"0001193125-26-248242","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure of shareholder vote results from ACADIA's Annual Meeting held May 29, 2026. The filing reports voting outcomes for three Class I director elections (James M. Daly, Edmund P. Harrigan, and Adora Ndu), advisory approval of named executive officer compensation, ratification of Ernst \u0026 Young LLP as auditor, and approval of a stock plan amendment increasing authorized shares by 5,209,670. All matters passed with substantial majorities, making this a material disclosure of governance and capital authorization decisions.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-30T02:13:01.237710+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":2706,"accession_number":"0001193125-26-248242","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of an amendment to the Company's 2024 Equity Incentive Plan that increases the aggregate number of shares authorized for issuance by 5,209,670 shares. This is a material compensatory arrangement affecting the equity incentive plan available to officers and directors. The filing explicitly references Item 5.02(e), which governs compensatory arrangements, and the amendment directly impacts the pool of equity available for future grants to named executives and directors.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-30T02:13:01.237710+00:00","company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","filing_date":"2026-05-29"},{"id":2707,"accession_number":"0001193125-26-248242","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure of shareholder vote results from ACADIA's Annual Meeting held May 29, 2026. The filing reports voting outcomes for three Class I director elections (James M. Daly, Edmund P. Harrigan, and Adora Ndu), advisory approval of named executive officer compensation, ratification of Ernst \u0026 Young LLP as auditor, and approval of a stock plan amendment increasing authorized shares by 5,209,670. All matters passed with substantial majorities, making this a material disclosure of governance and capital authorization decisions.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-30T02:13:01.237710+00:00","company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","filing_date":"2026-05-29"}]}